Merus (MRUS) investor relations material

Platform and pipeline overview

• Focus on oncology with a portfolio of clinical assets, including partnerships with major pharma companies.

• Bispecific antibody platform enables development of innovative therapies, leveraging established monoclonal antibody processes.

• Platform supports compatibility with standard antibody drug conjugate technologies.

• Three out of four clinical-stage assets show improved clinical success rates, including Biclonics® and petosemtamab.

Petosemtamab in colorectal cancer

• Petosemtamab targets EGFR and LGR5, with preclinical data showing strong activity in colorectal cancer models.

• LGR5 is expressed in a subset of colorectal cancer cells, believed to drive tumor growth and metastasis.

• Early phase 1 data in heavily pretreated colorectal cancer patients showed no responses, prompting a shift to earlier-line, genetically wild-type cohorts.

• Ongoing studies include three cohorts: first-line with chemo, second-line with chemo, and third-line monotherapy, with a clinical update expected in the second half of the year.

• Benchmarks for efficacy are based on cetuximab response rates (65% first-line, 30% second-line).

Petosemtamab in head and neck cancer

• Robust efficacy and safety data in both first- and second-line recurrent/metastatic head and neck cancer.

• First-line combination with pembrolizumab showed a 63% response rate and nearly 80% one-year survival, surpassing historical standards.

• Second-line monotherapy demonstrated a 36% response rate and median survival of 12.5 months, with favorable safety.

• Breakthrough therapy designation granted by FDA for both first- and second-line settings.

• Phase 3 registration trials ongoing, designed for potential accelerated approval under Project FrontRunner framework.